The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights
Osteosarcoma, the most aggressive primary malignant bone tumor, has stagnant therapeutic outcomes despite decades of standard MAP chemotherapy and surgery; 5‑year overall survival (OS) is <30% for metastatic/recurrent cases.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Systemic Therapy for Osteosarcoma and Ewing Sarcoma
- Potential proteins identified to target in osteosarcoma treatment
- Future Directions in the Treatment of Osteosarcoma
- Is There a Role for Mifamurtide in Nonmetastatic High‑Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS‑2) and Spanish Sarcoma Group (GEIS‑33) Trials
- The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights